Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naive Advanced Hepatocellular Carcinoma: Long-Term Follow-Up of Open-Label, Phase 2 KEYNOTE-224 Study

By afschroeder • March 3, 2026

Finn RS, Kudo M, Borbath I, Edeline J, Cattan S, van Vlierberghe H, Verslype C, Palmer D, Stål P, Ogasawara S, Vogel A, Chan SL, Knox JJ, Daniele B, Odeleye-Ajakaye A, Hatogai K, Siegel AB, Cheng AL, Van Laethem JL. Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naive Advanced Hepatocellular Carcinoma: Long-Term Follow-Up of Open-Label, Phase 2 KEYNOTE-224 Study. Clin Cancer Res. 2026 Mar 2. doi: 10.1158/1078-0432.CCR-25-3528. Epub ahead of print. PMID: 41770235.

Tags: Hematology/Oncology, Publications

Polycyclic aromatic hydrocarbons, gut microbiome composition, impulsivity, and attention covary in a human cohort

Hammer AJ, Kasschau KD, Davis Ii EW, Hoffman P, Johnson-Camacho K, Alexiev A, Anderson K, Shannon J, Marriott LK, Sharpton TJ. Polycyclic aromatic hydrocarbons, gut[...]

Tamibarotene with venetoclax and azacitidine in RARA+ acute myeloid leukemia: results from the SY-1425-202 study

Cluzeau T, Borate U, McMahon C, Fenaux P, Heiblig M, Peterlin P, Ball B, Chantepie S, Eghtedar A, Kambhampati S, Solh M, Torregrosa-Diaz J, Braun[...]

Real-World Management of Chronic Myelogenous Leukemia in an Underserved Patient Cohort at a Los Angeles Safety-Net Health System: Tyrosine Kinase Inhibitor Treatment Patterns and Outcomes From 2015 to 2024

Zheng D, Nold T, Ramakrishnan N, Kim K, Tomassetti S. Real-World Management of Chronic Myelogenous Leukemia in an Underserved Patient Cohort at a Los Angeles[...]